Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy.

The pharmacokinetics and time course of action of vecuronium in normal children and children receiving anticonvulsant drugs for prolonged periods were characterized. A bolus dose of vecuronium 0.15 mg kg(-1) was administered i.v. to 10 non-epileptic children and to 10 children on phenytoin and 10 children on carbamazepine, who were matched for age and weight. Plasma concentrations of vecuronium, 3-OH desacetylvecuronium (the primary metabolite of vecuronium) and alpha1-acid glycoprotein (AAG) were determined. Pharmacokinetic variables were derived from plasma samples collected before and after administration of vecuronium. Neuromuscular transmission was monitored by evoked compound electromyography. Recovery of the first twitch of the train-of-four (T1/T0) and the recovery index (RI), the time for 25-75% recovery of T1/T0, were determined. The elimination half-life of vecuronium was significantly reduced in both anticonvulsant groups compared with control [control 48.2 (SD 40.3), phenytoin 23.5 (13.1), carbamazepine 18.4 (16.6) min, P<0.05]. Vecuronium clearance was increased in both anticonvulsant groups [control 9.0 (3.6), phenytoin 15.1 (8.9), carbamazepine 18.8 (13.1) ml kg(-1) min(-1), 0.05<P<0.1]. Children on chronic anticonvulsant therapy had a significantly shorter RI than control [control 21.8 (11), phenytoin 12.5 (8.3), carbamazepine 10.6 (5.9) min, P<0.05]. Concentrations of vecuronium at different degrees of recovery of T1, volumes of distribution and AAG concentrations were not different between groups. Our data confirm anticonvulsant-induced resistance to vecuronium in children and support a pharmacokinetic component contributing to the resistance.

[1]  S. Soriano,et al.  Onset and duration of action of rocuronium in children receiving chronic anticonvulsant therapy , 2000, Paediatric anaesthesia.

[2]  H. Kress,et al.  Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. , 1999, Anesthesiology.

[3]  H. Kress,et al.  Atracurium–induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine , 1997, Acta anaesthesiologica Scandinavica.

[4]  I. Ramzan,et al.  Acute In Vitro Neuromuscular Effects of Carbamazepine and Carbamazepine-10,11-Epoxide , 1997, Anesthesia and analgesia.

[5]  M. Lamy,et al.  Elevated Plasma Alpha1-Acid Glycoprotein Levels: Lack of Connection to Resistance to Vecuronium Blockade Induced by Anticonvulsant Therapy , 1997, Journal of Neurosurgical Anesthesiology.

[6]  H. Kress,et al.  Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular block. , 1996, British journal of anaesthesia.

[7]  D. Whalley,et al.  Pharmacokinetic Origin of Carbamazepine-induced Resistance to Vecuronium Neuromuscular Blockade in Anesthetized Patients , 1996, Anesthesiology.

[8]  P. Yañez,et al.  Prolonged d-Tubocurarine Infusion and/or Immobilization Cause Upregulation of Acetylcholine Receptors and Hyperkalemia to Succinylcholine in Rats , 1996, Anesthesiology.

[9]  W. Jellish,et al.  Recovery From Mivacurium‐Induced Neuromuscular Blockade Is Not Affected by Anticonvulsant Therapy , 1996, Journal of neurosurgical anesthesiology.

[10]  M. J. Brodie,et al.  Drug therapy : antiepileptic drugs , 1996 .

[11]  J. Martyn,et al.  Basic and clinical pharmacology of the acetylcholine receptor: implications for the use of neuromuscular relaxants. , 1995, The Keio journal of medicine.

[12]  R. Miller,et al.  The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. , 1994, The Journal of pharmacology and experimental therapeutics.

[13]  R. Miller,et al.  Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing cadaver renal transplantation: a possible pharmacokinetic mechanism? , 1994, Anesthesiology.

[14]  P. Platt,et al.  Phenytoin-induced resistance to vecuronium. , 1993, Anaesthesia and Intensive Care.

[15]  G. Gronert,et al.  Prolonged duration of succinylcholine in patients receiving anticonvulsants: evidence for mild up-regulation of acetylcholine receptors? , 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[16]  J. Martyn,et al.  Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. , 1992, Anesthesiology.

[17]  F. Donati,et al.  High-performance liquid chromatography-electrochemical detection of vecuronium and its metabolites in human plasma. , 1992, Journal of chromatography.

[18]  M. Wood.  Plasma binding and limitation of drug access to site of action. , 1991, Anesthesiology.

[19]  J. Barré,et al.  Disease-Induced Variations in Plasma Protein Levels , 1990 .

[20]  J. Barré,et al.  Disease-Induced Variations in Plasma Protein Levels Implications for Drug Dosage Regimens (Part I) , 1990, Clinical pharmacokinetics.

[21]  R L Nation,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part II) , 1990, Clinical pharmacokinetics.

[22]  T. Pedley,et al.  The evaluation and treatment of seizures. , 1990, The New England journal of medicine.

[23]  J. Barré,et al.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II). , 1990, Clinical pharmacokinetics.

[24]  R. Milne,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part I) , 1990 .

[25]  R. Slater,et al.  The effect of acutely administered phenytoin on vecuronium‐induced neuromuscular blockade , 1989, Anaesthesia.

[26]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[27]  W. Young,et al.  The Effect of Phenytoin on the Magnitude and Duration of Neuromuscular Block Following Atracurium or Vecuronium , 1987, Anesthesiology.

[28]  G. Hartman,et al.  Succinylcholine: Mechanism of Fasciculations and Their Prevention by d‐Tubocurarine or Diphenylhydantoin , 1986, Anesthesiology.

[29]  W. Young,et al.  Resistance to Metocurine‐induced Neuromuscular Blockade in Patients Receiving Phenytoin , 1985, Anesthesiology.

[30]  Ronald D. Miller,et al.  Vecuronium kinetics and dynamics in anesthetized infants and children , 1985, Clinical pharmacology and therapeutics.

[31]  D. Greenblatt,et al.  Plasma protein binding of drugs after severe burn injury , 1984, Clinical pharmacology and therapeutics.

[32]  L. M. Liu,et al.  Safety and Efficacy of Vecuronium in Adolescents and Children , 1983, Anesthesia and analgesia.

[33]  R. Miller,et al.  Neuromuscular Effects of Vecuronium (ORG NC45) in Infants and Children during N2O, Halothane Anesthesia , 1983, Anesthesiology.

[34]  D. Greenblatt,et al.  Pharmacokinetics of d‐Tubocurarine in Patients with Thermal Injury , 1982, Anesthesia and analgesia.

[35]  B. Trommer,et al.  Differential effects of the anticonvulsants phenobarbital, ethosuximide and carbamazepine on neuromuscular transmission. , 1980, The Journal of pharmacology and experimental therapeutics.

[36]  D. Fellman.  ANTICONVULSANT THERAPY , 1980, Neurology.

[37]  Y. Yaari,et al.  Phenytoin: electrophysiological effects at the neuromuscular junction. , 1980, Advances in neurology.